Gri Bio, Inc. earnings releases GRI

Annual Quarterly

Gri Bio, Inc. last reported quarterly results on May 14, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): diluted EPS of -$1.61. It usually reports 35–45 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
May 14, 2026 44 days after quarter end	Q1 FY2026 ended Mar 31, 2026	—	-2 +34.4%	-1.61 +99.0%
Feb 4, 2026 35 days after quarter end	Q4 FY2025 ended Dec 31, 2025	—	-3 -36.5%	0.54 -94.1%
May 15, 2025 45 days after quarter end	Q1 FY2025 ended Mar 31, 2025	—	-3 -61.4%	-162.30 -60.6%
Nov 14, 2024 45 days after quarter end	Q3 FY2024 ended Sep 30, 2024	—	-2 +0.7%	-11.42 +82.6%
Aug 14, 2024 45 days after quarter end	— ended Jun 30, 2024	—	—	—
Apr 1, 2024 1 days after quarter end	— ended Mar 31, 2024	—	—	—
Nov 15, 2023 46 days after quarter end	— ended Sep 30, 2023	—	—	—
Aug 14, 2023 45 days after quarter end	— ended Jun 30, 2023	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: GRI (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: La Jolla, CA
SEC filer status: , Emerging growth company
SEC CIK: 1824293
Former names: Vallon Pharmaceuticals, Inc. (until Apr 21, 2023)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.